Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Earnings miss weighs on ChemoMetec shares despite record revenue and XcytoMatic growth

ChemoMetec reported an adjusted loss of -$1.15 per share in the fourth quarter (expectation -$0.80), while revenue of $124m was slightly above forecasts. For fiscal 2025/2026 the company posted record revenue of DKK 511m, an EBITDA margin of 55.0% and XcytoMatic growth of 146%. Management raised the outlook for 2026/2027 but remained cautious; investors focused on the earnings miss, sending the stock down about 6.2%. ChemoMetec plans higher investments in software, automation and protocol development and expects XcytoMatic to become the main growth driver going forward. » More on de.investing.com
ChemoMetec beats revenue forecasts for Q1 2025, stock falls nonetheless

ChemoMetec reported revenue of DKK 125m for the first quarter of 2025 (forecast DKK 124m) and earnings per share of 3.98. Revenue rose 8% in DKK (11% at constant exchange rates) and EBITDA was DKK 68.8m with a margin of 55%. Despite the positive figures, the stock fell about 4% to DKK 684. The company plans a phased rollout of the XM platform (soft launch 2026) and is strategically shifting toward software-based solutions. » More on de.investing.com
ChemoMetec stock rises 12.45% despite missed quarterly figures

ChemoMetec reported Q4 EPS of -$1.04 (expectation -$0.62) and revenue of $120m versus expected $128m. Restructuring costs weighed on results (total $12m, of which $8m in Q4). The stock nevertheless climbed 12.45% to $542 after management presented an optimistic outlook of 10–14% revenue growth, planned investments of $100m and new products (including Excitomatic XM40, XM50). Risks remain tariffs, currency fluctuations, intense competition and ongoing restructuring costs. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Chemometec has already paid €0.94 in dividends. The last payout was in October 2025.

Financials

In the last quarter, Chemometec had revenue of €35.06M and net profit of €14.43M

(EUR)	June 2026	YoY
Revenue	35.06M	-
Gross profit	22.43M	-
Net profit	14.43M	-
EBITDA	18.52M	-

Fundamentals

Metric	Value
Market capitalization	€1.63B
Number of shares	17.3M
52-week high/low	€106.46 - €31.44
Dividends	No
Beta	1.37
P/E ratio	60.86
PEG ratio	7.32
P/B ratio	16.93
P/S ratio	23.90

Company profile

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. The company was incorporated in 1997 and is headquartered in Allerød, Denmark.

Name	Chemometec
CEO	Martin Helbo Behrens
Headquarters	Allerød, cr Denmark
Website	chemometec.com
Sector	Health Care
Industry	Biotechnology
IPO	09/09/2015
Employees	174